Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyra Therapeutics (LYRA) Non-Current Assets (2021 - 2025)

Lyra Therapeutics (LYRA) has disclosed Non-Current Assets for 5 consecutive years, with $20.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Non-Current Assets fell 14.9% to $20.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $87.9 million, a 36.89% decrease, with the full-year FY2024 number at $23.3 million, down 38.27% from a year prior.
  • Non-Current Assets was $20.7 million for Q3 2025 at Lyra Therapeutics, down from $21.5 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $52.1 million in Q1 2024 to a low of $5.6 million in Q1 2021.
  • A 5-year average of $16.6 million and a median of $9.1 million in 2022 define the central range for Non-Current Assets.
  • Peak YoY movement for Non-Current Assets: skyrocketed 474.31% in 2024, then tumbled 56.97% in 2025.
  • Lyra Therapeutics' Non-Current Assets stood at $6.9 million in 2021, then surged by 31.52% to $9.1 million in 2022, then skyrocketed by 313.38% to $37.8 million in 2023, then plummeted by 38.27% to $23.3 million in 2024, then decreased by 11.28% to $20.7 million in 2025.
  • Per Business Quant, the three most recent readings for LYRA's Non-Current Assets are $20.7 million (Q3 2025), $21.5 million (Q2 2025), and $22.4 million (Q1 2025).